hygroton 50 mg comprimido
amdipharm ltd - clorotalidona - comprimido - 50 mg - clorotalidona 50 mg - chlortalidone - n/a - duração do tratamento: longa duração
hygroton 50 mg comprimido
amdipharm ltd - clorotalidona - comprimido - 50 mg - clorotalidona 50 mg - chlortalidone - n/a - duração do tratamento: longa duração
rekovelle
laboratÓrios ferring ltda - deltafolitropina - hormonio gonadotrofico
abecma
bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - agentes antineoplásicos - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
sivanto prime
bayer ag - solução concentrada (sl) com 17,1% (p/p) de flupiradifurona - butenolides
breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - agentes antineoplásicos - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
spiolto respimat 2.5 µg/dose + 2.5 µg/dose solução para inalação
boehringer ingelheim international gmbh - olodaterol + brometo de tiotrópio - solução para inalação - 2.5 µg/dose + 2.5 µg/dose - olodaterol, cloridrato 0.0027 mg/dose ; brometo de tiotrópio mono-hidratado 0.0031 mg/dose - adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids - n/a - duração do tratamento: longa duração
spiolto respimat 2.5 µg/dose + 2.5 µg/dose solução para inalação
boehringer ingelheim international gmbh - olodaterol + brometo de tiotrópio - solução para inalação - 2.5 µg/dose + 2.5 µg/dose - olodaterol, cloridrato 0.0027 mg/dose ; brometo de tiotrópio mono-hidratado 0.0031 mg/dose - adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids - n/a - duração do tratamento: longa duração
spiolto respimat 2.5 µg/dose + 2.5 µg/dose solução para inalação
boehringer ingelheim international gmbh - olodaterol + brometo de tiotrópio - solução para inalação - 2.5 µg/dose + 2.5 µg/dose - olodaterol, cloridrato 0.0027 mg/dose ; brometo de tiotrópio mono-hidratado 0.0031 mg/dose - adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids - n/a - duração do tratamento: longa duração
capecitabina
laboratorio quimico farmaceutico da aeronautica - capecitabina - outros antineoplasicos